pccmhub

Pulmonary & Critical Care Medicine education. Board-style questions, clinical pearls, and AI-powered learning. Built by physicians, for physicians PCCM trainees

[Dr. Chacón-Lozsán F .'. @franciscojlk]

🧠 Hypertonic Saline or Mannitol for Cerebral Edema?

Cerebral edema and intracranial hypertension remain among the most common life-threatening problems in neurocritical care. The Neurocritical Care Society guideline provides several practical bedside recommendations.

🔹 Hypertonic saline (HTS) is generally preferred over mannitol for acute ICP control in TBI and intracerebral hemorrhage due to more reliable and sustained ICP reduction.

🔹 Both HTS and mannitol effectively reduce ICP, but neither has consistently demonstrated improved long-term neurological outcomes.

🔹 In subarachnoid hemorrhage, symptom-triggered HTS boluses are favored over targeting a specific serum sodium concentration.

🔹 In acute ischemic stroke, either HTS or mannitol may be used, but routine prophylactic mannitol administration is discouraged.

🔹 Corticosteroids should not be used for intracerebral hemorrhage, as evidence suggests no benefit and potential harm.

🔹 The major exception is bacterial meningitis, where dexamethasone reduces neurological sequelae and should be administered before or with the first antibiotic dose.

⚠️ Safety matters. Severe hypernatremia (>155–160 mEq/L) and hyperchloremia (>110–115 mEq/L) are associated with increased risk of acute kidney injury and require close monitoring.

Take-home message: Hyperosmolar therapy remains a cornerstone of cerebral edema management, but treatment should be individualized according to the underlying neurological pathology rather than pursuing arbitrary sodium targets.

#NeurocriticalCare #ICU #CriticalCare #TBI #Stroke #SAH #ICH #CerebralEdema #HypertonicSaline #Mannitol #NeuroICU

Reference 📚

Cook AM, Jones GM, Hawryluk GWJ, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care. 2020;32:647-666. DOI: 10.1007/s12028-020-00959-7.

[pccmhub @pccmhub]

📄 CHEST 2017:
HAT therapy (hydrocortisone + ascorbic acid + thiamine) cut sepsis mortality 31%→8% in one observational study. RCTs pending.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

💡 OSA drives CV disease via sympathetic activation, endothelial dysfunction & inflammation. CPAP mitigates these pathways.

📚 https://t.co/ARgSGHQ63j
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

💡 HFNC first for acute hypoxemic respiratory failure; use NIV instead if cardiogenic pulmonary edema or COPD exacerbation.

📚 https://t.co/ARgSGHQ63j
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

✅ C) Osimertinib x3 years

ADAURA: adjuvant osimertinib 3 yrs improves DFS in resected stage IB–IIIA EGFR-mutated NSCLC.

📚 More at https://t.co/mhuk4mPe7J
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

🧠 Resected stage IIB EGFR exon 19-deleted NSCLC. Surgery went well. What's next per ADAURA?

#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 IDSA 2010:
Cryptococcal meningitis: induce with AmB + flucytosine, consolidate with fluconazole—don't skip induction.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 GINA 2020:
In kids ≤5y, asthma diagnosis is clinical—no spirometry; trial ICS therapy confirms diagnosis & guides management.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 GINA 2024:
GINA 2024: No SABA-only tx; all adults with asthma need ICS-containing therapy to reduce exacerbation & death risk.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 BTS 2023:
BTS 2023: Flexible bronchoscopy requires structured pre-assessment, tailored sedation & complication protocols for safe practice.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 GOLD 2024:
GOLD 2024: Individualize COPD therapy by symptoms & exacerbation risk—pharmacologic + non-pharmacologic strategies both matter.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 IDSA 2016:
Echinocandins are first-line for candidemia; fluconazole step-down after clinical stability & susceptibility confirmed.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 ERS 2020:
ERS 2020: Personalize asthma Rx—step up to biologics early in severe, uncontrolled disease before escalating oral steroids.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 ERS 2023:
2023 ERS COPD guidelines: personalize therapy, prevent exacerbations, and prioritize non-pharmacological care.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 IDSA 2019:
CAP guidelines: match antibiotic choice & care site to severity—PSI over CURB-65 preferred for site-of-care decisions.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

📋 GINA 2022:
GINA 2022: No SABA-only tx for asthma—all adults/adolescents need ICS-containing therapy as preferred or reliever.

📚 https://t.co/y61W0XvlPu
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

💡 Severe asthma: distinguish difficult-to-treat (adherence/comorbidities) from true therapy-resistant disease before escalating to biologics.

📚 https://t.co/ARgSGHQ63j
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

💡 HAP/VAP with MDR risk factors (prior IV antibiotics, septic shock, ARDS, ≥5 hospital days): cover MRSA + 2 Gram-negative classes empirically.

📚 https://t.co/ARgSGHQ63j
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

💡 VAP: 7-day therapy is non-inferior to longer courses for most patients. Extend only for necrotizing pneumonia or non-fermenters.

📚 https://t.co/ARgSGHQ63j
#PCCM #MedEd #CriticalCare

[pccmhub @pccmhub]

💡 Sarcoidosis Scadding stages I & II have higher spontaneous remission rates; stages III & IV carry risk of chronic progressive disease.

📚 https://t.co/ARgSGHQ63j
#PCCM #MedEd #CriticalCare